Proliv-Power IV Infusion

Recommended for provision of amino acids and energy in patients who require intravenous nutrition. Such conditions include surgery, infections, trauma, burns, prolonged disorders of the gastrointestinal tract, hypoproteinemia, malnutrition, preparation of patients for surgery, chemotherapy or radiation therapy, prolonged coma or refusal to eat.

Amino Acids-

• L-Arginine (as L-Arginine HCl) USP: 0.660 g
• L-Histidine (as L-Histidine HCl, H2O) BP: 0.300 g
• L-Isoleucine USP: 0.550 g
• L-Leucine USP: 1.230 g
• L-Lysine (as L-Lysine HC1) USP: 1.490 g
• L-Methionine USP: 0.710 g
• L-Phenylalanine USP: 0.870 g
• L-Threonine USP: 0.540 g
• L-Tryptophan USP: 0.180 g
• L-Valine USP: 0.610 g
• Glycine (Aminoacetic acid) USP: 1.000 g

Carbohydrate: D-Sorbitol BP: 5.000 g
Electrolytes: Sodium Chloride BP: 0.070 g

Amino acid injection with electrolytes provides crystalline amino acids to promote protein synthesis and wound healing and to reduce the rate of endogenous protein catabolism. Amino acid injection with electrolytes given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Amino acid injection with electrolytes can also be administered by peripheral vein with dextrose and maintenance electrolytes. Intravenous fat emulsion may be substituted for part of the carbohydrate calories during either TPN or peripheral vein administration of amino acid injection with electrolytes.

Generally proteins are provided in a daily dose of 0.8-1.0 g/kg for maintenance and 1.2-2.0 g/kg in catabolic states. The usual adult dosage is 500 ml via intravenous infusion over 200-250 minutes (40-30 drops/min). The dosage should be increased or decreased according to the age and body weight of the patient and the severity of the condition. The infusion rate should be slowed in elderly and severely ill patients. The maximal daily dose of sorbitol should not exceed 100 g. Slow intravenous administration is recommended.

At the recommended dosage the amino acids in this solutions have no pharmacological effects and is not expected to interact with other medicaments.

Hypersensitivity to any ingredient of the preparation. Hereditary fructose intolerance, hepatic coma, azotemia, congestive cardiac failure, severe acidosis and disturbances of amino acid metabolism.

Hypersensitivity, chest discomfort and palpitations may occur. Occasionally nausea, vomiting, chills, fever, phlebitis and electrolyte imbalance may occur.

This solution should be used in pregnant patients after careful assessment and only if the therapeutic benefits outweigh any potential risks associated with the treatment.

This solution should be administered with care in patients with severe hepatic and renal disorders, diabetes mellitus and in elderly.

Parenteral nutritional preparations

Protect from light and store at controlled room temperature. Avoid freezing. Keep medicaments out of reach of children